Publication: In vitro antiviral activity of spirotetronate compounds against dengue virus serotype 2
Issued Date
2019-01-01
Resource Type
ISSN
13498037
00221260
00221260
Other identifier(s)
2-s2.0-85065801326
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of General and Applied Microbiology. Vol.65, No.4 (2019), 197-203
Suggested Citation
Jirayut Euanorasetr, Bungonsiri Intra, Nutthanit Thunmrongsiri, Jitra Limthongkul, Sukathida Ubol, Atchareeya Anuegoonpipat, Takeshi Kurosu, Kazuyoshi Ikuta, Takuya Nihira, Watanalai Panbangred In vitro antiviral activity of spirotetronate compounds against dengue virus serotype 2. Journal of General and Applied Microbiology. Vol.65, No.4 (2019), 197-203. doi:10.2323/jgam.2018.10.001 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51132
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
In vitro antiviral activity of spirotetronate compounds against dengue virus serotype 2
Abstract
© 2019 Applied Microbiology, Molecular and Cellular Biosciences Research Foundation. Spirotetronate compounds are polyketide secondary metabolites with diverse biological functions, such as antibacterial, antitumor and antiviral activities. Three pure spirotetronate compounds (2EPS-A, -B, -C) isolated from Actinomadura strain 2EPS showed inhibitory activity against dengue virus serotype 2 (DENV-2). 2EPS-A, -B and -C demonstrated the LC50 values of 11.6, 27.5 and 12.0 mg/ ml, respectively, in a test of cytotoxicity to Vero cells. The least cytotoxic, 2EPS-B, was further analyzed for its impact on viral propagation in a cell-based replication assay. At a concentration of 6.25 mg/ml, it could reduce the DENV-2 infection in Vero cells by about 94% when cells infected with DENV-2 were exposed to 2EPS-B, whereas direct treatment of DENV-2 with 2EPS-B at the same concentration prior to subsequent infection to Vero cell yielded no inhibition. 2EPS-A, -B an -C showed strong DENV-2 NS2B-NS3 protease inhibition in an in vitro assay, with IC50 values of 1.94 ± 0.18, 1.47 ± 0.15 and 2.51 ± 0.21 mg/ml, respectively. Therefore, the spirotetronate compounds appear to prevent viral replication and viral assembly by inhibition of the viral protease.